Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Literature
1.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828CrossRefPubMed
2.
Coles AJ, CAMMS223 Trial Investigators Compston DAS, Selmaj KW, Lake SL, Moran S et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801CrossRefPubMed
3.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839CrossRefPubMed
4.
Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G et al (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46(3):296–304CrossRefPubMed
5.
Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996 98(12):2819–2826CrossRefPubMedPubMedCentral
6.
Caon C, Namey M, Meyer C, Mayer L, Oyuela P, Margolin DH et al (2015) Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and rebif® efficacy in multiple sclerosis (CARE-MS) program. Int J MS Care 17(4):191–198CrossRefPubMedPubMedCentral
7.
Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB, Haynes A et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23(13):2971–2979CrossRefPubMed
Metadata
Title
A case of anaphylaxis to alemtuzumab
Authors
Charles J. S. Nye
Annette Wagner
Onajite Kousin-Ezewu
Joanne L. Jones
Alasdair J. Coles
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 3/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09214-2

Other articles of this Issue 3/2019

Journal of Neurology 3/2019 Go to the issue

Original Communication

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey

Original Communication

Painful legs and moving toes syndrome evaluated through brain single photon emission computed tomography: a case series

Original Communication

Long-lasting diagonistic dyspraxia suppressed by rTMS applied to the right motor cortex

Original Communication

Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L: a systematic review

Original Communication

Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson’s disease

Original Communication

Incidence and mechanism of early neurological deterioration after endovascular thrombectomy